This review concluded that filaggrin gene defects increased the risk of allergic sensitisation and allergic disorders, but restoring skin barrier function early in life in individuals with filaggrin defects could prevent development of disorders. The authors' conclusions regarding increased risk appeared to reflect the evidence, but the conclusion regarding skin barrier function was speculative and should be interpreted with caution.
Study selection
Any genetic epidemiological study (family or case-control) investigating the relationship between filaggrin gene defects and allergic sensitisation or allergic disorders in humans of any ages and ethnic group were eligible for inclusion. Outcomes of interest were atopic eczema or dermatitis, food allergy, asthma, allergic rhinitis and anaphylaxis in addition to relevant immunological factors relating to the risk of allergic sensitisation assessed by positive skin prick testing or increased levels of allergen specific Immunoglobulin E (IgE).
Included studies were mostly conducted in western Europe and North America. Where reported, the setting was usually in hospital. Most studies included participants with the filaggrin gene mutations R501X and 2282del4. Tn some studies carriers were compared to non-carriers. Patients had atopic dermatitis (persistent or early onset) or eczema. Diagnoses were made using the following methods: assessed by a dermatologist or allergologist according to various definitions; Hanfin and Rajka criteria; Williams et al criteria; questionnaires or scales; increased IgE levels; or skin prick tests. Most studies were matched for ethnicity and some were also matched for sex and/or age.
Two reviewers screened papers for inclusion. Disagreements were resolved by discussion.
Assessment of study quality
A customised checklist was developed to assess the quality of the included studies, including criteria on participant selection, validity of the approach to genotyping, population stratification and statistical considerations. Studies were described as high, medium or poor quality. The authors did not state how many reviewers performed the validity assessment.
Data extraction
Odds ratios and their 95% confidence intervals were calculated for individual case control studies. For familial studies, the transmission of possible alleles A and B from parents to an affected offspring were translated into odds ratios. P values for the association between filaggrin gene defects and outcomes of interest were also extracted. Where there was a zero in the contingency table, 0.5 was added. Study authors were contacted for further details if necessary. The authors did not state how many reviewers performed the data extraction. Where possible, a random-effects model was used to combine odds ratios and their 95% confidence intervals. Subgroup analyses were conducted for the two most common mutations (R501X and 2282del4). Sensitivity analyses were conducted for study quality, hospital setting and disease severity (persistent or early onset). Where meta-analysis was not possible, data were presented as a narrative synthesis and reported in the review.
Methods of synthesis
Statistical heterogeneity was assessed using the Cochran's Q (p value) and I 2 tests. Publication bias was assessed using funnel plots.
Results of the review
Twenty four studies were included in the review: four family/case control studies (n=1,785 families, n=1,263 cases, n=2,084 controls); 14 case control studies (n=2,559, n=5,807); three family studies (n=1,342 families); two crosssectional studies (n=3,973); and one cohort study (n=882). Studies were classed as B or C in terms of quality, but it was unclear what level of quality this represented.
Allergic sensitisation
Combined filaggrin gene defects were shown to increase the risk of allergic sensitisation, odds ratio 1.57 (95% confidence interval: 1.20, 2.07; two case-control study arms) and odds ratio 1.91 (95% confidence interval: 1.44, 2.54; five family study arms). However, there was evidence of statistical heterogeneity (p<0.001, I 2 =72.20).
Atopic eczema/dermatitis
Combined filaggrin gene defects increased the risk of atopic dermatitis, odds ratio 4.78 (95% confidence interval: 3.31, 6.92; 11 case control study arms) and odds ratio 1.99 (95% confidence interval: 1.72, 2.31; six family study arms). Subgroup analyses and sensitivity analyses confirmed the positive associations. One cohort study showed that filaggrin gene mutations increased the risk of eczema during the first year of life in a Danish cohort, odds ratio 2.26 (95% confidence interval: 1.27, 4.00) and an English cohort, odds ratio 1.95 (95% confidence interval: 1.13, 3.36).
Allergic rhinitis
Combined filaggrin gene defects were shown to increase the risk of allergic rhinitis in participants with atopic dermatitis, odds ratio 2.84 (95% confidence interval: 2.08, 3.88; two case-control study arms), odds ratio 2.46 (95% confidence interval: 1.61, 3.76; two family study arms) and in patients without atopic dermatitis, odds ratio 1.78 (95% confidence interval: 1.16, 2.73; two case control study arms).
Asthma
There was no significant increase in the risk of asthma in participants with combined filaggrin gene defects without atopic dermatitis or eczema (one family study and three case-control studies). However, participants with combined filaggrin gene defects with atopic dermatitis or eczema were shown to be at increased risk of developing asthma, odds ratio 2.79 (95% confidence interval: 1.77, 4.41; five case-control studies), odds ratio 2.30 (95% confidence interval: 1.66, 3.18; seven family study arms).
Subgroup analyses for gene mutations R501X and 2282del4 showed positive associations in terms of sensitisation, atopic eczema/dermatitis and asthma.
There were no studies assessing the association between filaggrin gene defects and the risk of developing food allergies or anaphylaxis. Where publication bias was assessed, this was not found to be present.
